Pfizer, a major player in the Streptomyces Derivatives Market, notably acquired Array BioPharma in July 2019. This merger brought advanced genetics and biotechnology capabilities to Pfizer, potentially enabling innovative applications of Streptomyces derivatives. Array BioPharma's expertise in cancer research also provides new avenues for therapeutic applications of Streptomyces-derived antibiotics.